Influenza Vaccines Market projected to exceed $6 Billion by 2025

DUBLIN–(BUSINESS WIRE)–The “Influenza
Vaccines Market: Global Industry Analysis, Share, Size, Growth,
Opportunity and Forecast 2019-2025” report has been added to ResearchAndMarkets.com’s
offering.

The global influenza vaccines market size is expected to surpass USD 6
billion by 2025.

Influenza Vaccines Market: Global Industry Analysis, Share, Size,
Growth, Opportunity and Forecast 2019-2025 presents an in-depth
assessment of the global influenza vaccines market dynamics,
opportunities, future roadmap, competitive landscape and discusses major
trends. The report offers the most up-to-date industry data on the
actual market situation and future outlook for the global influenza
vaccines market. The report includes historical data from 2013 to 2018
and forecasts until 2025.

The report contains a granular analysis of the present industry
situations, market demands, reveal facts on the market size, revenues
and provides forecasts through 2025. The report provides clear insight
into current and future developments of the global influenza vaccines
market. The report also explores detailed analysis of the number of
persons being vaccinated with influenza vaccines globally from 2013 to
2018 and forecasts to 2025.

Additionally, the report includes assessment of clinical trials,
promising influenza vaccines in the clinical development and rapid
diagnostic testing for the management of influenza. It also provides a
deep and thorough evaluation of the distribution channel and technique
of the influenza vaccination. Key trends in terms of collaboration,
merger & acquisition, distribution, exclusive and licensing agreement
are analyzed with details. The report also explores the detailed
description of growth drivers and inhibitors of the global influenza
vaccines market.

Further, prudent analysis has been done on the competitor’s part, where
four major players grab a major share of the global influenza vaccine
market by net sales. Sanofi Pasteur, GlaxoSmithKline (GSK), Seqirus (CSL
Limited) and AstraZeneca are the key influencers with their vaccines in
the global influenza vaccines market. Other emerging players such as
Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, BiondVax
Pharmaceuticals Ltd, Altimmune, FluGen, Moderna, Vaccitech, VaxInnate,
and BioDiem are making novel technology-based influenza vaccine which is
likely to affect the market share during the forecast period.

The report concludes with the profiles of major players in the global
influenza vaccines market. The key market players are evaluated on
various parameters such as company overview, influenza vaccines
portfolios, sales value analysis and recent development in the global
influenza vaccines market.

The Latest Industry Data Included in this Report:

• • Global Influenza Vaccines Market Size and Analysis (2013 – 2025)
  • Global Number of Persons Vaccinated with Influenza Vaccines (2013 –
    2025)
  • Global Influenza Vaccines Market Share Analysis and Forecast (2013 –
    2025)
  • Global Number of Persons Vaccinated with Influenza Vaccines Share and
    Forecast (2013 – 2025)
  • Global Influenza Vaccines Market in Top 21 Countries and Forecast
    (2013 – 2025)
  • Rapid Diagnostic Testing for the Management of Influenza
  • Global Distribution Channel and Technique of Influenza Vaccination
  • Promising Influenza Vaccines in Clinical Development
  • Major Deals in the Global Influenza Vaccines Market
  • Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
  • Market Definition for the Specified Topic Along with Identification of
    Key Drivers and Inhibitors for the Market
  • A Comprehensive List of Key Market Players Along with the Analysis of
    their Current Vaccines Portfolios, Sales Value Analysis, and Recent
    Development

The Report Answers the Following Questions:

• • How has the global influenza vaccines market performed so far and how
    will it perform in the coming years?
  • What are the key markets in the global influenza vaccines industry?
  • How many numbers of persons being vaccinated with influenza vaccines
    globally during 2013 – 2025?
  • What are the key drivers and inhibitors in the current market?
  • What are the various influenza vaccines available globally?
  • How is the market predicted to develop in the future?
  • Who are the key players in this market space?

Key Topics Covered

1. Executive Summary

2. Global Number of Persons Vaccinated with Influenza Vaccines
(2013 – 2025)

3. Global Influenza Vaccines Market Size and Analysis (2013 –
2025)

4. Global Influenza Vaccines Market Share Analysis and Forecast
(2013 – 2025)

4.1 Global Number of Persons Vaccinated with Influenza Vaccines Share
and Forecast

4.2 Global Influenza Vaccines Market Share and Forecast

5. Key Drivers and Inhibitors of the Global Influenza Vaccines
Market

5.1 Market Drivers

5.2 Market Inhibitors

6. Global Influenza Vaccines Market in Top 21 Countries –
Geographical Landscape (Volume and Value) (2013 – 2025)

6.1 United States

6.1.1 United States Number of Persons Vaccinated with Influenza Vaccines
(2013 – 2025)

6.1.2 United States Influenza Vaccines Market Size & Analysis (2013 –
2025)

6.2 Canada

6.3 Germany

6.4 France

6.5 Italy

6.6 Spain

6.7 United Kingdom

6.8 Netherlands

6.9 Sweden

6.10 Denmark

6.11 Poland

6.12 Norway

6.13 Finland

6.14 Ireland

6.15 Belgium

6.16 Australia

6.17 New Zealand

6.18 Japan

6.19 Brazil

6.20 China

6.21 India

6.22 Other Countries

7. Rapid Diagnostic Testing for the Management of Influenza

8. Global Distribution Channel and Technique of Influenza
Vaccination

9. Promising Influenza Vaccines in Clinical Development

10. Major Deals in the Global Influenza Vaccines Market

10.1 Merger& Acquisitions

10.2 Collaboration Deal

10.3 Licensing Agreement

10.4 Exclusive Agreement

10.5 Distribution Agreement

11. Influenza Vaccines Clinical Trial Insights by Phase, Company
& Country

11.1 Year 2018

11.2 Year 2017

12. Key Companies Analysis

12.1 Sanofi Pasteur

12.1.1 Business Overview

12.1.2 Influenza Vaccines Portfolio

12.1.3 Influenza Vaccine Value Sales Analysis

12.1.4 Recent Development

12.2 GlaxoSmithKline (GSK)

12.3 Seqirus (CSL Limited)

12.4 AstraZeneca

12.5 Sinovac Biotech Ltd.

12.6 Gamma Vaccines Pty Ltd.

12.7 Hualan Biological Engineering Inc.

12.8 Shanghai Institute of Biological Products Co. Ltd.

12.9 Mylan

12.10 BioDiem

For more information about this report visit https://www.researchandmarkets.com/r/4efumg

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Vaccines